BT-600 is a drug/device combination delivering a liquid formulation of tofacitinib via the NaviCap™ platform for the treatment of ulcerative colitis
IND application is supported by robust clinical device function data
https://www.biospace.com/article/releases/biora-therapeutics-announces-submission-of-ind-application-to-the-u-s-fda-for-bt-600-program/
Note: Only a member of this blog may post a comment.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.